TITLE

Effectiveness of second generation antipsychotics: A systematic review of randomized trials

AUTHOR(S)
Johnsen, Erik; Jørgensen, Hugo
PUB. DATE
January 2008
SOURCE
BMC Psychiatry;2008, Vol. 8, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Systematic reviews based on efficacy trials are inconclusive about which second generation antipsychotic drug (SGA) should be preferred in normal clinical practice, and studies with longer duration and more pragmatic designs are called for. Effectiveness studies, also known as naturalistic, pragmatic, practical or real life studies, adhere to these principles as they aim to mimic daily clinical practice and have longer follow-up. Objective: To review the head-to-head effectiveness of SGAs in the domains of global outcomes, symptoms of disease, and tolerability. Methods: Searches were made in Embase, PubMED, and the Cochrane central register of controlled trials for effectiveness studies published from 1980 to 2008, week 1. Different combinations of the keywords antipsychotic*, neuroleptic* AND open, pragmatic, practical, naturalistic, real life, effectiveness, side effect*, unwanted effect*, tolera* AND compar* AND random* were used. Results: Sixteen different reports of randomized head-to-head comparisons of SGA effectiveness were located. There were differences regarding sample sizes, inclusion criteria and follow-up periods, as well as sources of financial sponsorship. In acute-phase and first-episode patients no differences between the SGAs were disclosed regarding alleviating symptoms of disease. Olanzapine was associated with more weight gain and adverse effects on serum lipids. In the chronic phase patients olanzapine groups had longer time to discontinuation of treatment and better treatment adherence compared to other SGAs. The majority of studies found no differences between the SGAs in alleviating symptoms of psychosis in chronically ill patients. Olanzapine was associated with more metabolic adverse effects compared to the others SGAs. There were surprisingly few between-drug differences regarding side effects. First generation antipsychotics were associated with lower total mental health care costs in 2 of 3 studies on chronically ill patients, but were also associated with more extrapyramidal side effects compared to the SGAs in several studies. Conclusion: In chronically ill patients olanzapine may have an advantage over other SGAs regarding longer time to treatment discontinuation and better drug adherence, but the drug is also associated with more metabolic side effects. More effectiveness studies on first-episode psychosis are needed.
ACCESSION #
35702786

 

Related Articles

  • The Problems with CATIE Phase 1: Looking Back--What the Clinician Needs to Know. Washburn Jr., Carl F. // Connecticut Medicine;Apr2008, Vol. 72 Issue 4, p223 

    The article discusses the problems with the Clinical Antipsychotic Trials of Interventional Effectiveness (CATIE) Phase 1 Trial, which was intended as a randomized and controlled clinical trial comparing the second-generation antipsychotic (SGA) agents risperidone, olanzapine, quetiapine and...

  • Olanzapine: hyperglycaemia and diabetes.  // WHO Drug Information;2004, Vol. 18 Issue 1, p32 

    Reports on the U.S. Food & Drug Administration's request to manufacturers of atypical antipsychotics to add a warning statement describing the risk of hyperglycemia and diabetes. Updates in the prescribing information for olanzapine; Monitoring of patients with diabetes who are started on...

  • Alterations to Melanocortinergic, GABAergic and Cannabinoid Neurotransmission Associated with Olanzapine-Induced Weight Gain. Weston-Green, Katrina; Xu-Feng Huang; Chao Deng // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Background/Aim: Second generation antipsychotics (SGAs) are used to treat schizophrenia but can cause serious metabolic side-effects, such as obesity and diabetes. This study examined the effects of low to high doses of olanzapine on appetite/ metabolic regulatory signals in the hypothalamus and...

  • Induction of manic symptoms by novel antipsychotics. Fahy, S.; Fahy, T. J. // British Journal of Psychiatry;Jun2000, Vol. 176, p597 

    A letter to the editor is presented which reports a case of 55-year-old woman with a 20-year history of chronic anxiety and recurrent depressive episodes who developed subjective excitement, increased psychomotor activity, insomnia, irritability and racing thoughts within three days of being...

  • Noise and health in vulnerable groups: A review. van Kamp, Irene; Davies, Hugh // Noise & Health;May/Jun2013, Vol. 15 Issue 64, p153 

    Vulnerable or susceptible groups are mentioned in most reviews and documents regarding noise and health. But only a few studies address this issue in a concrete and focused way. Groups at risk most often mentioned in the literature are children, the elderly, the chronically ill and people with a...

  • Uncovering Treatment Burden as a Key Concept for Stroke Care: A Systematic Review of Qualitative Research. Gallacher, Katie; Morrison, Deborah; Jani, Bhautesh; Macdonald, Sara; May, Carl R.; Montori, Victor M.; Erwin, Patricia J.; Batty, G. David; Eton, David T.; Langhorne, Peter; Mair, Frances S. // PLoS Medicine;Jun2013, Vol. 10 Issue 6, p1 

    Background: Patients with chronic disease may experience complicated management plans requiring significant personal investment. This has been termed 'treatment burden' and has been associated with unfavourable outcomes. The aim of this systematic review is to examine the qualitative literature...

  • Association between Drug Insurance Cost Sharing Strategies and Outcomes in Patients with Chronic Diseases: A Systematic Review. Mann, Bikaramjit S.; Barnieh, Lianne; Tang, Karen; Campbell, David J. T.; Clement, Fiona; Hemmelgarn, Brenda; Tonelli, Marcello; Lorenzetti, Diane; Manns, Braden J. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Background: Prescription drugs are used in people with hypertension, diabetes, and cardiovascular disease to manage their illness. Patient cost sharing strategies such as copayments and deductibles are often employed to lower expenditures for prescription drug insurance plans, but the impact on...

  • Effects of quercetin supplementation on lipid profile: A systematic review and meta-analysis of randomized controlled trials. Sahebkar, Amirhossein // Critical Reviews in Food Science & Nutrition;2017, Vol. 57 Issue 4, p666 

    Background: In spite of promising experimental findings, randomized controlled trials (RCTs) have yielded mixed results on the impact of quercetin supplementation on plasma lipid levels. Aim: The present study aimed to quantify the effects of quercetin on plasma lipids using a meta-analysis of...

  • British Columbia selects drug reviewers. Banaszek, Adrianna // CMAJ: Canadian Medical Association Journal;3/22/2011, Vol. 183 Issue 5, pE254 

    The article reports on the selected teams to conduct drug reviews in British Columbia including the University of British Columbia (UBC) Faculty of Medicine, Providence Health Care Research Institute, and British Columbia Drug and Poison Information Centre. It says that the UBC team will be led...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics